Using data from registries across Europe and Canada, Aymon et al. did not observe an increased incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase (JAK) inhibitors compared with those treated with other biologic disease-modifying anti-rheumatic drugs. Their findings support similar cardiovascular risk profiles for JAK and tumor necrosis factor inhibitors.
Latest News
Mouth-Watering Possibilities in Sjögren’s Disease
New ACR guidelines for SARD-associated interstitial lung disease cover key recommendations for screening, monitoring and first-line treatment options.
Sjögren’s Disease: More Than Just a Syndrome
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
How to Diagnose Sjögren’s Disease
Improve your Sjögren’s disease diagnosis. Experts discuss objective testing, seronegative cases, ILD screening & management strategies.
How the Experts Treat Sjögren’s Disease
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
